Second Xiangya Hospital
Changsha, Hunan, 410011, China
NCT Number: NCT07444463
Previous and our studies have shown that cognitive impairments are core symptoms of three major psychiatric disorders-schizophrenia, bipolar disorder, and major depressive disorder, and are associated with underlying brain dysfunction. However, the specific brain networks involved in cognitive impairments (cognitive impairment brain networks) in these disorders, as well as whether their neuroimaging features can be applied to cognitive assessment, diagnosis, and precision treatment, remain unclear. This study aims to identify cognitive impairment brain networks using publicly available large-scale datasets and clinical research, and to explore whether the neuroimaging features of these networks can be utilized for cognitive assessment, diagnosis, and treatment response prediction. First, a "sensitive cognitive assessment model for major psychiatric disorders" will be established through meta-analysis based on sensitive scales. Second, cognitive impairment brain networks will be identified using publicly available large-scale datasets combined with the lesion network mapping method, and their validity will be examined by assessing their non-randomness, reproducibility, symptom specificity, and disease specificity. Third, cognitive assessment and diagnostic models will be developed based on neuroimaging features of these networks. Finally, a combination of cross-sectional and longitudinal study designs will be used in a clinical trial to validate the identified networks and models, and a treatment response prediction model will be established based on the neuroimaging features of cognitive impairment brain networks. This study will advance the understanding of the neurophysiological mechanisms underlying cognitive impairment in major psychiatric disorders, promote the application of neuroimaging in psychiatric diagnosis and treatment, and improve traditional diagnostic, therapeutic, and cognitive assessment approaches.
Trial opening soon.
Get Notified18 year–60 year
All sexes
Interventional
Not applicable
Changsha, Hunan, 410011, China
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Diagnosis of schizophrenia (SZ), bipolar disorder (BD), or major depressive disorder (MDD) according to standard diagnostic criteria
First-episode drug-naïve patients or patients who have relapsed after discontinuing medication for more than one month
Aged 18-60 years
Completion of at least 6 years of formal education
2, For Healthy Controls:
Aged 18-60 years
Completion of at least 6 years of formal education
No current or past psychiatric disorders
No first-degree relatives with psychiatric disorders
No history of treatment with psychotropic medications or physical therapy for psychiatric disorders
Exclusion criteria
Contraindications to MRI scanning
History of brain injury
History of substance abuse
Presence of other neurological disorders
Presence of severe medical or systemic physical illnesses.
Patients will receive repetitive transcranial magnetic stimulation (rTMS) targeting the dorsolateral prefrontal cortex (dlPFC).
Time frame: From enrollment to the end of treatment at 8 weeks
Cognitive Changes Assessed with the MATRICS Consensus Cognitive Battery (MCCB) after Repetitive Transcranial Magnetic Stimulation (rTMS) Intervention
Contact information is provided by the study sponsor or research team.
Central South University
Other
Study on the Brain Network Mechanisms of Cognitive Impairments in Major Psychiatric Disorders and Their Application in Cognitive Assessment, Diagnosis, and Precision Treatment
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07479758
Bipolar Disorder, Bipolar and Related Disorders
Hangzhou, Zhejiang, China
View Trial DetailsNCT07549581
Bipolar Disorder, Bipolar and Related Disorders
Los Alamitos, California, United States
View Trial DetailsNCT06898879
Behavior, Bipolar Disorder
San Diego, California, United States
View Trial DetailsNCT06748950
Acid-Base Imbalance, Acidosis
Palo Alto, California, United States
View Trial Details